Patents by Inventor Marina Ciomei

Marina Ciomei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10478423
    Abstract: The present invention relates to substituted indazole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by degulated protein kinase activity, like cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: November 19, 2019
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Andrea Lombardi Borgia, Marina Ciomei, Daniele Donati, Marcella Nesi
  • Publication number: 20180289672
    Abstract: The present invention relates to substituted indazole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by degulated protein kinase activity, like cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.
    Type: Application
    Filed: June 20, 2018
    Publication date: October 11, 2018
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Andrea Lombardi Borgia, Marina Ciomei, Daniele Donati, Marcella Nesi
  • Patent number: 10028934
    Abstract: The present invention relates to substituted indazole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by degulated protein kinase activity, like cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: July 24, 2018
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Andrea Lombardi Borgia, Marina Ciomei, Daniele Donati, Marcella Nesi
  • Patent number: 9597317
    Abstract: The present invention relates to substituted indazole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by degulated protein kinase activity, like cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.
    Type: Grant
    Filed: July 6, 2016
    Date of Patent: March 21, 2017
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Andrea Lombardi Borgia, Marina Ciomei, Daniele Donati, Marcella Nesi
  • Publication number: 20160311776
    Abstract: The present invention relates to substituted indazole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by degulated protein kinase activity, like cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.
    Type: Application
    Filed: July 6, 2016
    Publication date: October 27, 2016
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Andrea Lombardi Borgia, Marina Ciomei, Daniele Donati, Marcella Nesi
  • Publication number: 20160310465
    Abstract: The present invention relates to substituted indazole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by degulated protein kinase activity, like cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.
    Type: Application
    Filed: July 6, 2016
    Publication date: October 27, 2016
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Andrea Lombardi Borgia, Marina Ciomei, Daniele Donati, Marcella Nesi
  • Patent number: 9408850
    Abstract: The present invention relates to substituted indazole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by degulated protein kinase activity, like cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: August 9, 2016
    Assignee: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Andrea Lombardi Borgia, Marina Ciomei, Daniele Donati, Marcella Nesi
  • Patent number: 8946226
    Abstract: The invention provides a low molecular weight ATP-competitive CDK inhibitor able to cross the blood brain barrier for use in the treatment of malignant glioma and, in particular, of glioblastoma. The compound can be administered together with one or more agents selected from the group consisting of cytotoxic or cytostatic agents and ionizing radiation.
    Type: Grant
    Filed: July 28, 2009
    Date of Patent: February 3, 2015
    Assignee: Nerviano Medical Sciences S.r.l.
    Inventors: Marina Ciomei, Francesco Fiorentini, Enrico Pesenti
  • Patent number: 8912194
    Abstract: The invention provides a low molecular weight ATP-competitive CDK inhibitor for use in the treatment of mesothelioma. The compound can be administered together with one or more cytotoxic or cytostatic agents.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: December 16, 2014
    Assignee: Nerviano Medical Sciences S.R.L.
    Inventors: Marina Ciomei, Angela Scaburri
  • Publication number: 20140080807
    Abstract: The present invention relates to substituted indazole compounds which modulate the activity of protein kinases and are therefore useful in treating diseases caused by degulated protein kinase activity, like cancer. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing such these compounds or the pharmaceutical compositions containing them.
    Type: Application
    Filed: May 7, 2012
    Publication date: March 20, 2014
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Andrea Lombardi Borgia, Marina Ciomei, Daniele Donati, Marcella Nesi
  • Patent number: 8580793
    Abstract: The invention provides a low molecular weight ATP-competitive CDK inhibitor and TRKA inhibitor of formula (I) for use in the treatment of thymoma and thymic carcinoma. The compound can be administered together with one or more cytotoxic or cytostatic agents.
    Type: Grant
    Filed: March 15, 2010
    Date of Patent: November 12, 2013
    Assignee: Nerviano Medical Services S.r.l.
    Inventors: Angela Scaburri, Maria Adele Pacciarini, Marina Ciomei, Bernard Laffranchi, Silvia Comis
  • Patent number: 8518930
    Abstract: The present invention provides a therapeutic combination comprising (a) a compound of formula (I) as set forth in the specification and (b) one or more antineoplastic agents selected from the group consisting of alkylating or alkylating-like agents, antimetabolite agents and topoisomerase I inhibitors, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof.
    Type: Grant
    Filed: July 29, 2009
    Date of Patent: August 27, 2013
    Assignee: Nerviano Medical Sciences S.r.l.
    Inventors: Marina Ciomei, Aurelio Marsiglio, Valter Domenico Croci, Enrico Pesenti
  • Publication number: 20120077819
    Abstract: The invention provides a low molecular weight ATP-competitive CDK inhibitor and TRKA inhibitor of formula (I) for use in the treatment of thymoma and thymic carcinoma. The compound can be administered together with one or more cytotoxic or cytostatic agents.
    Type: Application
    Filed: March 15, 2010
    Publication date: March 29, 2012
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Angela Scaburri, Maria Adele Pacciarini, Marina Ciomei, Bernard Laffranchi, Silvia Comis
  • Publication number: 20110312909
    Abstract: The present invention provides a therapeutic combination comprising (a) a compound of formula (I) as set forth in the specification and (b) one or more antineoplastic agents selected from the group consisting of alkylating or alkylating-like agents, antimetabolite agents and topoisomerase I inhibitors, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof.
    Type: Application
    Filed: July 29, 2009
    Publication date: December 22, 2011
    Applicant: Nerviano Medical Sciences S.r.l.
    Inventors: Marina Ciomei, Aurelio Marsiglio, Valter Domenico Croci, Enrico Pesenti
  • Publication number: 20110224222
    Abstract: The invention provides a low molecular weight ATP-competitive CDK inhibitor for use in the treatment of mesothelioma. The compound can be administered together with one or more cytotoxic or cytostatic agents.
    Type: Application
    Filed: November 23, 2009
    Publication date: September 15, 2011
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Marina Ciomei, Angela Scaburri
  • Publication number: 20110190311
    Abstract: The invention provides a low molecular weight ATP-competitive CDK inhibitor able to cross the blood brain barrier for use in the treatment of malignant glioma and, in particular, of glioblastoma. The compound can be administered together with one or more agents selected from the group consisting of cytotoxic or cytostatic agents and ionizing radiation.
    Type: Application
    Filed: July 28, 2009
    Publication date: August 4, 2011
    Applicant: NERVIANO MEDICAL SCIENCES S.R.L.
    Inventors: Marina Ciomei, Francesco Fiorentini, Enrico Pesenti
  • Publication number: 20090074757
    Abstract: The present invention provides the combined use of acryloyl distamycin derivatives, in particular ?-homo- and ?-chloro-acryloyl distamycin derivatives of formula (I), as set forth in the specification, and an antibody inhibiting a growth factor or its receptor, in the treatment of tumors. Also provided is the use of the said combinations in the treatment or prevention of metastasis or in the treatment of tumors by inhibition of angiogenesis.
    Type: Application
    Filed: March 29, 2006
    Publication date: March 19, 2009
    Inventors: Enrico Pesenti, Marina Ciomei, Maria Cristina Geroni
  • Publication number: 20050288238
    Abstract: A compound which is a benzocyclodecane of the formula I: wherein: at positions 8-9 and 11-12 independently represents a single or double bond, —R1 is ?O, or —OR7, R7 is H, C1-C7 alkanoyl, benzoyl, C1-C10 alkyl, C2-C10 alkenyl or COCH?CHR8, R8 is aryl or heterocyclyl; —R2 and —R3 are H, ?O or —OR9, R9 is H, C1-C7 alkanoyl or benzoyl; when at position 11-12 there is a single bond, then —R4 represents ?O, ?CH2, ?CHCOOR10, R10 is C1-C10 alkyl or aryl; ?CH(OCH3), —OR9; —CH2OR11, R11 is H or a sugar residue, —COR12, R12 is H, —OH or —OR10; or when at position 11-12 there is a double bond, then —R4 is —CH2OR11 or —COR12; —R5 and —R6 are H or, when at position 8-9 there is a single bond, taken together form a cyclopropane ring; R13 is H or 1-3 substituents selected from C1-C6 alkyl, C2-C6 alkenyl, phenyl, phenyl C1-C6 alkyl, halogen, hydroxy, C1-C6 alkoxy, aryloxy, cyano, nitro, amino, C1-C10 alkylamino, arylamino, C1-C7 alkanoylamino, aroylamino, hydroxycarbonyl, aminocarbonyl, C1-C6 alkylcarbonyl, C1-C6
    Type: Application
    Filed: June 28, 2004
    Publication date: December 29, 2005
    Inventors: Mauro Angiolini, Sylvie Ducki, Maria Menichincheri, Nicola Mongelli, Ermes Vanotti, Marina Ciomei
  • Publication number: 20050038112
    Abstract: There are provided sarcodictyin derivatives or pharmaceutically acceptable salts thereof, which are characterized by a simplified chemical structure and have anti-tumor activity. A process for their preparation, the pharmaceutical compositions containing them, and their use in the prevention, control and treatment of cancer are also provided.
    Type: Application
    Filed: September 6, 2002
    Publication date: February 17, 2005
    Inventors: Nicola Mongelli, Maria Menichincheri, Marina Ciomei, Cesare Gennari, Joachim Telser, Raphael Beumer
  • Patent number: 6187758
    Abstract: An anthracycline glycoside of formula I wherein R is one of the two following residues: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 27, 1999
    Date of Patent: February 13, 2001
    Assignee: Pharmacia & Upjohn S.p.A.
    Inventors: Cinzia Portello, Emanuele Arlandini, Umberto Breme, Anna Luisa Colombo, Giuliano Franchi, Giuliano Oronzo, Marco Tató, Luisa Garofano, Marina Ciomei